Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ayisha Sharma

Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from the University College London. Ayisha is especially interested in the clinical landscape for rare diseases. Outside of work, she has written for several lifestyle and culture publications including The Kraze and M&S Vmag.

Latest From Ayisha Sharma

Enanta’s Path Forward Uncertain After RSV Failure

The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.

Clinical Trials Respiratory

Gene Therapy Biotechs Treating Sanfilippo Syndrome Hit Cash Crunch

Despite promising clinical data and solid regulatory plans, biotech firms hoping to address the unmet need in Sanfilippo Syndrome through gene therapy are facing financial struggles.

Companies Gene Therapy

Valneva Hits New COVID-19 Jab Low With EC Contract Termination

Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.

Coronavirus COVID-19 Vaccines

Beckley Psytech Takes On Rare Disease With Psychedelics

Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.

Emerging Company Profile Neurology

The Top Five Biopharma Alliances Of Q1

With the help of Biomedtracker’s Dealmaking Quarterly Statistics report, Scrip takes a look at the five biggest alliances by value in the first quarter and how they could shape the future of the companies involved, from big pharma to biotech.

Companies Deals

European Biomanufacturing SPAC Launched, Backed By Former Sanofi-Aventis CEO Le Fur

EureKING hopes to help develop and manufacture novel cell and gene therapies and live biotherapeutics, among other types of biologics, through a number of strategic acquisitions.

Companies Manufacturing
See All
UsernamePublicRestriction

Register